Skip to content

Study · Case report or series · n = 1 · 2026

3 results

Angioedema After Accidental Semaglutide Dosing Error: A Case Report.

Kraft BD, Matuszak S

Journal of clinical medicine12 May 2026

PMID42194666 (opens in a new tab)PMCIDPMC13207423 (opens in a new tab)DOI10.3390/jcm15103705 (opens in a new tab)PepBankPUB-42194666
Download PDFPubMedAsk about this study
Jump to 3 results

Summary

Background: Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use has increased exponentially as studies show significant benefits in cardiovascular and renal diseases and obesity. Accessibility to the public also increased after compounding pharmacies began direct-to-consumer distribution. Gastrointestinal side effects are common; however, hypersensitivity reactions are rare. Case Presentation: A 50-year-old female with a history of obesity, hypertension, and lisinopril-induced angioedema presented to the Emergency Department with swelling of the lips, tongue, and throat developing four hours after her first injection of compounded semaglutide for weight loss. She was treated with epinephrine, corticosteroids, and antihistamines, but due to progressive airway edema, she required intubation and mechanical ventilation for four days. After extubation, she reported accidentally injecting a ten-fold higher dose (2 mg) of semaglutide than was appropriate for the first dose. The hospitalization was complicated by hypoglycemia requiring dextrose infusion, but was otherwise unremarkable, and she was discharged home on day 7. Based on the temporal onset after semaglutide injection, this presentation was most consistent with GLP-1 RA-induced angioedema. While she also had a history of lisinopril-induced angioedema five years earlier, and had been taking valsartan for hypertension, the remoteness of the lisinopril exposure made this less likely. Conclusions: Semaglutide use may be associated with severe angioedema within hours of administration. Given the overlapping indications and patient populations, angioedema appearing in patients taking both GLP-1 RAs and ACE inhibitors may become increasingly common and present a diagnostic dilemma. Diagnosis of hypersensitivity to GLP-1 RAs can be supported with history and positive skin testing. Clinicians should be aware that inexperienced patients are at the highest risk of dosing errors.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 50-year-old woman, swelling of the lips, tongue and throat (angioedema) developed four hours after her first injection of compounded semaglutide, and was judged most consistent with GLP-1 RA-induced angioedema.

    In plain wordsIn one woman, severe swelling of the lips, tongue and throat began four hours after a first semaglutide injection.

    Peptide
    Semaglutide
    Outcome
    Not applicableAngioedema after semaglutide injection
    Study

    n = 1

    Outcome group
    Adverse events · Immune and inflammation
    Studied dose
    2 mg (accidental first dose) · injection · single doseAs given in this study (human).

    Source sentences

    Summary
    A 50-year-old female with a history of obesity, hypertension, and lisinopril-induced angioedema presented to the Emergency Department with swelling of the lips, tongue, and throat developing four hours after her first injection of compounded semaglutide for weight loss.
    1 context sentence
    Summary · context
    Based on the temporal onset after semaglutide injection, this presentation was most consistent with GLP-1 RA-induced angioedema.
  2. 02HumanCase report or seriesSafety outcome

    In the same patient, progressive airway edema after semaglutide injection required intubation and mechanical ventilation for four days despite epinephrine, corticosteroids and antihistamines.

    In plain wordsIn this woman, airway swelling got worse and she needed a breathing tube and a ventilator for four days.

    Peptide
    Semaglutide
    Outcome
    Not applicableAirway edema requiring intubation
    Study

    n = 1

    Outcome group
    Adverse events · Respiratory
    Studied dose
    2 mg (accidental first dose) · injection · single doseAs given in this study (human).

    Source sentences

    Summary
    She was treated with epinephrine, corticosteroids, and antihistamines, but due to progressive airway edema, she required intubation and mechanical ventilation for four days.
    1 context sentence
    Summary · context
    A 50-year-old female with a history of obesity, hypertension, and lisinopril-induced angioedema presented to the Emergency Department with swelling of the lips, tongue, and throat developing four hours after her first injection of compounded semaglutide for weight loss.
  3. 03HumanCase report or seriesSafety outcome

    In the same patient, who had injected 2 mg semaglutide as a first dose, the hospital stay was complicated by hypoglycemia that required a dextrose infusion.

    In plain wordsIn this woman, who had injected a ten-fold higher dose by mistake, low blood sugar needed treatment with a dextrose infusion.

    Peptide
    Semaglutide
    Outcome
    Not applicableHypoglycemia requiring dextrose infusion
    Study

    n = 1

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    2 mg (accidental first dose) · injection · single doseAs given in this study (human).

    Source sentences

    Summary
    The hospitalization was complicated by hypoglycemia requiring dextrose infusion, but was otherwise unremarkable, and she was discharged home on day 7.
    1 context sentence
    Summary · context
    After extubation, she reported accidentally injecting a ten-fold higher dose (2 mg) of semaglutide than was appropriate for the first dose.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.